The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| JNJ | +20.09% | +51.19% | +8.61% | +102,217% |
| S&P | +16.9% | +95.99% | +14.39% | +6,967% |
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The MedTech segment offers products used in the interventional solutions. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.
Get step-by-step guidance on investing in Johnson & Johnson stock and learn the ins and outs of this healthcare company.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $23.99B | 6.8% |
| Gross Profit | $16.73B | 7.6% |
| Gross Margin | 69.72% | 0.5% |
| Market Cap | $446.55B | 14.5% |
| Market Cap / Employee | $3.19M | 0.0% |
| Employees | 139.8K | 6.0% |
| Net Income | $5.15B | 91.2% |
| EBITDA | $8.89B | 27.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $18.23B | -8.8% |
| Accounts Receivable | $17.61B | 8.9% |
| Inventory | 14.1K | 12.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $39.41B | 25.9% |
| Short Term Debt | $6.39B | 43.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 13.54% | 5.0% |
| Return On Invested Capital | 15.64% | -0.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $8.01B | 15.0% |
| Operating Free Cash Flow | $9.17B | 14.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 25.02 | 18.20 | 16.30 | 17.34 | -34.99% |
| Price to Book | 4.96 | 5.58 | 4.70 | 5.69 | 4.30% |
| Price to Sales | 3.96 | 4.44 | 4.07 | 4.74 | 5.99% |
| Price to Tangible Book Value | -24.64 | -38.65 | -118.00 | -22.91 | -26.95% |
| Price to Free Cash Flow TTM | 43.90 | 47.08 | 57.06 | 59.28 | 36.76% |
| Enterprise Value to EBITDA | 67.51 | 50.85 | 45.61 | 52.16 | -10.84% |
| Free Cash Flow Yield | 2.3% | 2.1% | 1.8% | 1.7% | -26.88% |
| Return on Equity | 20.1% | 29.4% | 30.2% | 33.6% | 60.94% |
| Total Debt | $37.83B | $52.25B | $50.76B | $45.80B | 28.09% |
We also take a look at Chewy's growth initiatives.
Plus, we run through some shortcuts that could help you with your financial planning.
Plus, a look at the 4% rule and a common misconception about retirement spending.
Plus a look at what to like about Johnson & Johnson.
JNJ earnings call for the period ending December 31, 2024.
JNJ earnings call for the period ending September 30, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
